MT-2 (Melanotan II)
10mg
MT-2 10mg
Research Compound Lyophilized Powder
New Releases

MT-2 (Melanotan II)

Non-Selective Melanocortin Agonist

$45.00
Third-Party Lab Tested
COA With Every Order
Fast U.S. Shipping
Text Email

What It Is

A synthetic cyclic heptapeptide analog of α-MSH that acts as a non-selective agonist across multiple melanocortin receptors (MC1R, MC3R, MC4R, MC5R). Originally developed at the University of Arizona as a research tool for studying melanocortin-mediated pigmentation pathways.

How It Works

1
MT-2 binds melanocortin receptors (MC1R, MC3R/4R/5R)
→
2
Melanocyte adenylate cyclase is activated
→
3
Eumelanin synthesis is upregulated
→
4
Pigmentation and centrally mediated pathways are studied

What Researchers Study It For

MC1R / melanogenesis pathway studies
Cyclic peptide melanocortin pharmacology
Photoprotection model investigations
Multi-receptor melanocortin signaling research

Common Research Protocols

In published research, MT-2 has been reconstituted with bacteriostatic water and administered subcutaneously at low-microgram-per-kg doses, with literature noting cumulative pigmentation responses over multi-week protocols in animal models.

Community Interest Areas

The dermatology and melanocortin-pharmacology research community has studied MT-2 since the 1980s as the prototype non-selective melanocortin agonist — used to map receptor distribution, melanin biosynthesis, and the broader physiology of MC1R–MC5R. Its non-selective profile is what makes it a valuable comparator against more recently developed selective agonists.

Non-Selective Agonist across MC1R, MC3R, MC4R, and MC5R
Prototype Studied since the 1980s in melanocortin pharmacology

For research purposes only. Not intended for consumption, clinical application, or diagnostic use.

Research Fundamentals

What Are Peptides?

How peptides work at the cellular level — receptor binding, tissue repair, immune modulation, and metabolic function.

Read Article → Safety & Compliance

Are Peptides Safe?

An honest look at peptide safety — what research shows, the 2026 FDA reclassification, source quality, and key considerations.

Read Article →
Learn About Peptides